Katarina Halpin Veszeleiova, PhD
About Katarina Halpin Veszeleiova, PhD
Katarina Luptakova is a seasoned medical professional and Chief Medical Officer with extensive experience in hematology/oncology and clinical development.
Katarina Luptakova Chief Medical Officer
Katarina Luptakova is the Chief Medical Officer with a wealth of experience in the medical field. She has held significant roles in both clinical practice and pharmaceutical development. As Chief Medical Officer, she brings extensive expertise in hematology and oncology, bolstered by her comprehensive clinical and academic background.
Katarina Luptakova Education and Training
Katarina Luptakova received her medical degree from Comenius University School of Medicine in Bratislava, Slovakia. Following her graduation, she completed an internal medicine residency at St. Elizabeth's Medical Center in Boston. She further refined her expertise with a fellowship in hematology/oncology at Beth Israel Medical Center, which is part of Harvard Medical School. This rigorous training provided her with a solid foundation for her subsequent roles in clinical practice and research.
Katarina Luptakova Professional Background
Katarina Luptakova has a distinguished professional background. She was an attending physician in the bone marrow transplant and malignant hematology division at Beth Israel Deaconess Medical Center in Boston, Massachusetts. In this role, she contributed significantly to clinical practice and patient care in the field of hematology and oncology.
Katarina Luptakova Achievements in Clinical Development
Katarina Luptakova has made notable contributions in the pharmaceutical industry. As vice president of clinical development at Constellation Pharmaceuticals, Inc., she played a pivotal role through its acquisition by MorphSys AG. Additionally, at Tesaro, Inc., she served as senior medical director and clinical lead, where she notably contributed to the development and commercialization of Zejula (niraparib) and Blenrep (belantamab mafodotin-blmf), both critical advancements in cancer treatment.